Keros Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Keros Therapeutics, Inc. (KROS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 870.50 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-03
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 45.56K shares, a 45.76% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 824.94K shares.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 84.00K shares, a 94.89% decline from fiscal 2024.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.64M shares, a 18.54% increase from fiscal 2023.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.39M shares, a 27.60% increase from fiscal 2022.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.09M shares, a 44.78% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 45.56K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 870.50K shares 10-Q · filed 2026-08-03 | 870.50K shares derived: sum of 3 quarters · filed 2026-08-03 | 870.50K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 824.94K shares 10-Q · filed 2026-05-14 | 824.94K shares derived: sum of 2 quarters · filed 2026-05-14 | 824.94K shares derived: sum of 3 quarters · filed 2026-05-14 | 908.94K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-04 | 84.00K shares derived: sum of 3 quarters · filed 2026-03-04 | 84.00K shares 10-K · filed 2026-03-04 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 84.00K shares derived: sum of 2 quarters · filed 2025-11-05 | 84.00K shares 10-Q · filed 2025-11-05 | 299.50K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 84.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 84.00K shares 10-Q · filed 2025-08-06 | 299.50K shares derived: sum of 3 quarters · filed 2025-08-06 | 387.30K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-06 | 215.50K shares derived: sum of 2 quarters · filed 2025-05-06 | 303.30K shares derived: sum of 3 quarters · filed 2025-05-06 | 479.90K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 215.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 303.30K shares derived: sum of 2 quarters · filed 2025-02-26 | 479.90K shares derived: sum of 3 quarters · filed 2025-02-26 | 1.64M shares 10-K · filed 2025-02-26 |
| 2024-09-30 | 87.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 264.40K shares derived: sum of 2 quarters · filed 2024-11-06 | 1.43M shares 10-Q · filed 2024-11-06 | 1.52M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 176.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 1.34M shares 10-Q · filed 2024-08-07 | 1.43M shares derived: sum of 3 quarters · filed 2024-08-07 | 1.56M shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 1.16M shares 10-Q · filed 2024-05-08 | 1.26M shares derived: sum of 2 quarters · filed 2024-05-08 | 1.39M shares derived: sum of 3 quarters · filed 2024-05-08 | 1.72M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 93.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 224.90K shares derived: sum of 2 quarters · filed 2024-02-28 | 559.40K shares derived: sum of 3 quarters · filed 2024-02-28 | 1.39M shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 131.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 466.00K shares derived: sum of 2 quarters · filed 2023-11-06 | 1.29M shares 10-Q · filed 2023-11-06 | 1.38M shares derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | 334.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 1.16M shares 10-Q · filed 2023-08-07 | 1.24M shares derived: sum of 3 quarters · filed 2023-08-07 | 1.35M shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 826.89K shares 10-Q · filed 2023-05-04 | 909.70K shares derived: sum of 2 quarters · filed 2023-05-04 | 1.02M shares derived: sum of 3 quarters · filed 2023-05-04 | 1.27M shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 82.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | 189.10K shares derived: sum of 2 quarters · filed 2023-03-03 | 445.06K shares derived: sum of 3 quarters · filed 2023-03-03 | 1.09M shares 10-K · filed 2023-03-03 |
| 2022-09-30 | 106.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 362.26K shares derived: sum of 2 quarters · filed 2022-11-03 | 1.00M shares 10-Q · filed 2022-11-03 | 1.15M shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 255.96K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 897.36K shares 10-Q · filed 2022-08-04 | 1.04M shares derived: sum of 3 quarters · filed 2022-08-04 | 1.16M shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 641.40K shares 10-Q · filed 2022-05-05 | 786.70K shares derived: sum of 2 quarters · filed 2022-05-05 | 908.30K shares derived: sum of 3 quarters · filed 2022-05-05 | 984.56K shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 145.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | 266.90K shares derived: sum of 2 quarters · filed 2022-03-09 | 343.16K shares derived: sum of 3 quarters · filed 2022-03-09 | 750.41K shares 10-K · filed 2022-03-09 |
| 2021-09-30 | 121.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 197.86K shares derived: sum of 2 quarters · filed 2021-11-04 | 605.11K shares 10-Q · filed 2021-11-04 | 637.70K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 76.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 483.51K shares 10-Q · filed 2021-08-05 | 516.10K shares derived: sum of 3 quarters · filed 2021-08-05 | 545.00K shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 407.25K shares 10-Q · filed 2021-05-06 | 439.84K shares derived: sum of 2 quarters · filed 2021-05-06 | 468.74K shares derived: sum of 3 quarters · filed 2021-05-06 | 1.86M shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 32.59K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 61.49K shares derived: sum of 2 quarters · filed 2021-03-25 | 1.45M shares derived: sum of 3 quarters · filed 2021-03-25 | 1.45M shares 10-K · filed 2021-03-25 |
| 2020-09-30 | 28.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 1.42M shares derived: sum of 2 quarters · filed 2020-11-10 | 1.42M shares 10-Q · filed 2020-11-10 | |
| 2020-06-30 | 1.39M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | 1.39M shares 10-Q · filed 2020-08-13 | ||
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |